Personalized mRNA vaccine plus immunotherapy for lung cancer
Part of Cancer, Lungs & breathing clinical trials.
This trial tests a personalized mRNA vaccine (made from your tumor's unique markers) combined with the immunotherapy drug adebrelimab for people with non-small cell lung cancer. It may help your immune system fight cancer cells that remain after standard treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 to 75 years old.
- You have non-small cell lung cancer (NSCLC) that either didn't fully respond to chemo-immunotherapy before surgery, or has spread and progressed after one prior treatment.
- You are willing to provide a tumor sample for genetic testing and give blood samples before and after treatment.
- Your overall health is good (ECOG 0 or 1), and your vital organs function well (heart, liver, kidneys, blood counts).
- You do not have an autoimmune disease, active infections, or other serious health conditions that would interfere with the trial.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a personalized mRNA vaccine made from your tumor's unique mutations. It's given after surgery to help your immune system fight any remaining cancer cells and prevent the cancer from coming back.
This trial tests adding the immunotherapy drug Adebrelimab to standard chemotherapy before surgery for people with stage II or III non-small cell lung cancer (the most common type) that can be removed. The goal is to see if this combination shrinks tumors more effectively and improves outcomes.
This trial tests a new cancer vaccine (RGL-270) combined with immunotherapy drugs for advanced non-small cell lung cancer. The vaccine is designed to train your immune system to recognize and fight your specific cancer.
This trial tests a combination of radiation, immunotherapy (QL1706), and chemotherapy given before surgery for non-small-cell lung cancer that can be removed. It aims to see if this approach can shrink the tumor and improve outcomes.
This study tests a combination of a personalized vaccine made from your tumor's unique markers, a type of immunotherapy (PD-1 inhibitor), and radiation. The goal is to see if this mix can work better for advanced lung cancer that has progressed after initial treatment.
This trial tests a combination of a personalized vaccine (made from your tumor's unique markers), a drug that boosts your immune system (PD-1 inhibitor), and targeted radiation for people with advanced lung cancer that has progressed after initial treatment. The goal is to see if this combination can help shrink tumors or slow the cancer's growth.
Hear when a new NSCLC trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.